home  lumithera new treatment for agerelated macular degeneration photobiomodulation pbm in agerelated macular degeneration lumithera is a developmental stage medical device company created by a team of founder physicians scientists and engineers experienced in photobiomodulation pbm fields for ocular diseases and disorders lumithera is at the forefront in the development of pbm treatment protocols for agerelated macular degeneration about us lumithera is a medical device company focused on led and laser treatments for acute and chronic ocular disease research led instruments are being developed for the treatment of agerelated macular degeneration diabetic retinopathy and other ocular indications products planning and development of ophthalmological devices that use light emitting diodes leds which provide low level noncoherent light treatments opportunity emerging clinical data highlight an exciting new opportunity to improve visual acuity in the elderly with agerelated macular degeneration with photobiomodulation pbm lumithera named most innovative and promising medtech  ehealth company at biovision   lumithera new treatment for agerelated macular degeneration lumithera named most innovative and promising medtech  ehealth company at biovision  seattle april   prnewswire — lumithera® inc a clinical stage medical device company focused on delivering noninvasive photobiomodulation pbm therapies for ocular disorders and disease today announced it has been awarded the prestigious “most innovative and promising medtech  ehealth company” during biovision  in lyon france biovision is a highlevel investor event connecting industrial partners financial investors and the best medical technology biotechnology and ehealth startup and midsize companies biovisionorg the most promising companies in each category are awarded based upon key criteria such as societal benefit market attractiveness innovative approach competitive position team structure and attractiveness for investment this is the second year that lumithera received the top award in its respective categories in  lumithera was the winner in the catalyzer category and this year it won first place in the investor category on a unanimous vote selected from a pool of applicants by a special biovision committee companies with the greatest potential to offer innovative health solutions were invited to present during the biovision forum in front of a jury comprised of leading european private and corporate investors in the life sciences “we are delighted that biovision has recognized the scientific clinical and product development progress lumithera made over the last year in advancing towards the commercial introduction of our innovative technology for treating dry age related macular degeneration amd one of the leading causes of blindness in the world” said clark tedford phd chief executive officer “we are honored to have received this second award as we prepare to bring this important therapy to the millions of patients suffering from dry amd who have no other treatment alternatives” about age related macular degeneration amd agerelated macular degeneration amd accounts for  of all blindness worldwide and is the most common cause of blindness according to the world health organization disease prevalence is likely to increase due to population aging approximately 5 of amd is the “dry” form of the disease the emotional and socioeconomic impact of amd is large because vision impairment caused by the disease which primarily affects central straighton rather than peripheral side vision can severely impact daily activities such as reading and driving about lumithera inc lumithera inc is a developmentalstage medical device company initially focused on treating patients affected by dry agerelated macular degeneration the company’s expertise is in the application of photobiomodulation “pbm” using noninvasive light emitting diodes “led” for acute and chronic ocular diseases and disorders the company is developing an ophthalmic led officebased instrument to be used in multiple ocular conditions or disorders as noninvasive medical treatments two clinical studies have demonstrated clinical and pathological benefits of pbm in treating subjects with dry amd the recent torpa ii clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in december  in acta ophthalmologica a top peerreviewed ophthalmology journal the company is currently testing their lt device in a thirty subject dry amd study partially supported by the national eye institute this randomized sham controlled clinical study is fully enrolled and interim outcomes are expected in  the lt is currently in clinical trials and is not ce marked nor fda k cleared  lumithera inc all rights reserved visit the company’s website at wwwlumitheracom source lumithera inc leave a reply cancel reply commentyou may use these html tags and attributes a href title abbr title acronym title b blockquote cite cite code del datetime em i q cite s strike strong name required email required will not be published website   lumithera named most innovative and promising medtech  ehealth company at biovision  lumithera named most innovative and promising medtech  ehealth company at biovision  news provided by lumithera inc apr    et share this article seattle april   prnewswire  lumithera® inc a clinical stage medical device company focused on delivering noninvasive photobiomodulation pbm therapies for ocular disorders and disease today announced it has been awarded the prestigious most innovative and promising medtech  ehealth company during biovision  in lyon france biovision is a highlevel investor event connecting industrial partners financial investors and the best medical technology biotechnology and ehealth startup and midsize companieshttpwwwbiovisionorg the most promising companies in each category are awarded based upon key criteria such as societal benefit market attractiveness innovative approach competitive position team structure and attractiveness for investment this is the second year that lumithera received the top award in its respective categories in  lumithera was the winner in the catalyzer category and this year it won first place in the investor category on a unanimous vote selected from a pool of applicants by a special biovision committee companies with the greatest potential to offer innovative health solutions were invited to present during the biovision forum in front of a jury comprised of leading european private and corporate investors in the life sciences  we are delighted that biovision has recognized the scientific clinical and product development progress lumithera made over the last year in advancing towards the commercial introduction of our innovative technology for treating dry age related macular degeneration amd one of the leading causes of blindness in the world said clark tedford phd chief executive officer we are honored to have received this second award as we prepare to bring this important therapy to the millions of patients suffering from dry amd who have no other treatment alternatives about age related macular degeneration amd agerelated macular degeneration amd accounts for  of all blindness worldwide and is the most common cause of blindness according to the world health organization disease prevalence is likely to increase due to population aging approximately 5 of amd is the dry form of the disease the emotional and socioeconomic impact of amd is large because vision impairment caused by the disease which primarily affects central straighton rather than peripheral side vision can severely impact daily activities such as reading and driving about lumithera inc lumithera inc is a developmentalstage medical device company initially focused on treating patients affected by dry agerelated macular degeneration the companys expertise is in the application of photobiomodulation pbm using noninvasive light emitting diodes led for acute and chronic ocular diseases and disorders the company is developing an ophthalmic led officebased instrument to be used in multiple ocular conditions or disorders as noninvasive medical treatments two clinical studies have demonstrated clinical and pathological benefits of pbm in treating subjects with dry amd the recent torpa ii clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological drusen following imaging analysis were published in december  in acta ophthalmologica a top peerreviewed ophthalmology journal the company is currently testing their lt device in a thirty subject dry amd study partially supported by the national eye institute this randomized sham controlled clinical study is fully enrolled and interim outcomes are expected in  the lt is currently in clinical trials and is not ce marked nor fda k cleared  lumithera inc all rights reserved visit the companys website at wwwlumitheracom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleaseslumitheranamedmostinnovativeandpromisingmedtechehealthcompanyatbiovision44html source lumithera inc related links httpwwwlumitheracom may    et preview lumithera presents results of torpa ii clinical study at the association for research in vision and ophthalmology arvo conference my news release contains wide tables view fullscreen you just read lumithera named most innovative and promising medtech  ehealth company at biovision  news provided by lumithera inc apr    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version lumithera receives lsdf commercialization grant award lumithera receives lsdf commercialization grant award may 2   et from lumithera inc seattle may 2  prnewswire  lumithera inc a developmental stage medical device company creating a noninvasive photobiomodulation pbm treatment for ocular disorders and disease announced today that they were awarded a washington state life sciences discovery fund lsdf commercialization grant lumithera was  of  recipients of the lsdf matching grants worth  to provide for commercialization activities for a treatment for subjects with dry agerelated macular degeneration amd lsdf executive director john desrosier stated our track record shows that lsdf grants help commercialize major medical breakthroughs and attract private funding from external investors according to the lsdf press release these new awards help move promising treatments and diagnostics more quickly from the lab bench to patients in need we are very honored for the continuing support of the lsdf award program  the seed grant allowed us to build a prototype instrument and now this matching investor commercialization grant will allow us to complete the commercial product development stated clark tedford phd president and ceo there are no approved treatments for dry amd except vitamin supplements the grant with investor matching funds will further support initiation of a pivotal clinical trial in subjects that have dry amd  since the lsdf announcement we have secured the investor match and will prepare for a clinical trial later this year retired congressman norm dicks recently appointed to the advisory team at lumithera shared this insight the use of the lsdf funds demonstrates the direct impact on creating new jobs and establishing viable business in washington the grant also provides for collaboration between lumithera and seattlebased product creation studio pcs a design house that has been working with the company to create the novel instrument the prototype build went very well and lumithera is now poised to bring this to market stated scott thielman vice president pcs lumithera has generated some exciting pilot human data with their pbm approach says dr rob devenyi ophthalmologistinchief and director of retinal services university of toronto the use of pbm could give a large number of patients a noninvasive treatment wherein there are no alternatives  if it can slow the progression of vision loss that would be a tremendous advance in the field visit the companys website at wwwlumitheracom about lumithera inc lumithera is a developmentalstage medical device company focused on treating people affected by dry agerelated macular degeneration the company was founded by a team of physicians scientists and engineers with backgrounds in the use of photobiomodulation pbm using noninvasive light emitting diodes led and laser treatments for acute and chronic ocular diseases and disorders the company is developing an ophthalmologist led officebased instrument to be used in multiple ocular conditions or disorders as noninvasive medical treatments  lumithera inc all rights reserved source lumithera inc related links httpwwwlumitheracom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more sep   4 et preview lumithera receives notice of awards for two national eye institute grants may   2 et preview retired congressman norman dicks joins lumitheras advisory team my news release contains wide tables view fullscreen read more apr    et lumithera named most innovative and promising medtech  ehealth more news releases in biotechnology health care  hospitals medical equipment medical pharmaceuticals awards looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search lumithera wins k grant for pbm devices  rapidscan  aug   biophotonics menu photonics media buyers guide edu photonics register login publications news features products technologies education media webinars events subscribe advertise about us bookstore search this week in photonicslight matters monthly alertphotonics spectra newsletterbiophotonics newslettereurophotonics newsletterasiapacific photonics newsletterphotonics showcase newsletterspectroscopy newslettertradeshow sneak previewsindustrial photonics lasers newsletterindustrial photonics vision newsletterphotonics in defense  aerospace newsletterphotonics media bookstore alerttechnology newsletters about us bookstore subscribe advertise login register publications view all our magazines photonics spectra industrial photonics biophotonics europhotonics photonics showcase reference photonics buyers guide photonics handbook photonics dictionary eduphotonicscom view all newsletters this week in photonicslight matters monthly alertphotonics spectra newsletterbiophotonics newslettereurophotonics newsletterphotonics showcase newsletterspectroscopy newslettertradeshow sneak previewsindustrial photonics lasers newsletterindustrial photonics vision newsletter services subscribe reader service advertise mobile apps news view all latest news business research  technology editors picks better materials could advance design of dielectric nanophotonic devices hours agolightactivated gene expression could uncover cancer therapies day agouniversity of arizona receives surveillance grant for border patrol day agohayne developing quantum technology patent for telecommunications day agoan international meeting of optical minds day ago in case you missed it novel photopatterning builds oleds from the ground up editorial how to submit a press release view all newsletters subscribe to weekly or montlhy alerts follow us features latestsmartphone fluorescence microscopy allows costeffective molecular diagnosticslack of diagnostic tools in resourcelimited settings remains one of the major obstacles to disease diagnosis and treatment in the developing world although significant progress has been made in thebiophotonics aug more featuresphotonics spectra jul laser beam diagnostics is a critical step in university researchphotonics spectra jul chalcogenide glass molding advances precision ir opticsbiophotonics aug in dermatology lasers offer options for medical cosmetic proceduresbiophotonics aug spectroscopy and the holy grailindustrial photonics jul measuring surface features with high resolution in factory environmentseurophotonics jun interweaving photonics research industryphotonicscom sep machine vision helps adhesive trend stick in auto industry editorial how to submit a feature idea products view alllatestspectroradiometerthe spectraval 5 spectroradiometer from jeti technische instrumente gmbh has been announced bysphereoptics gmbhultrafast framing cameraspecialised imagingoptimized bespoke ir lensesresolve optics ltd view allphotonics showcaseusb shutterthe picard industries usbshutter offers a compact and simple method of automating the blocking ofpicard industries view allphotonics prodspecoptics custom spherical mirrorsroutinely manufactures both concave and convex spherical mirrors in virtually any material andbmv optical technologies inc promote your product enter to win a prism award for photonics innovation how to submit a product press release advertise technologies view alllaserslightactivated gene expression could uncover cancer therapieshayne developing quantum technology patent for telecommunicationslaser diode driverportable power systems inc view allopticsbetter materials could advance design of dielectric nanophotonic devicesan international meeting of optical mindsoptimized bespoke ir lensesresolve optics ltd view allimaginguniversity of arizona receives surveillance grant for border patrolharvard mit researchers use google maps to study gentrification urban planningultrafast framing cameraspecialised imaging other technologies biophotonics industrial sensors  detectors test  measurement light sources fiber optics spectroscopy microscopy materials  coatings education view allwhite papersautonomous automobiles don’t operate underwater however…autonomous vehicles use an assortment of sensors and imagers including lidar light detection and ranging whether it’s scanning system solid state or flash these systems need to be calibrated forlabsphere inc photonics view allphotonics handbooklaser operation temperature control and mount selectionas you operate your laser only a portion of the electrical power sourced from your laser driver converts to light energy the remainder turns to heat and the buildup of that thermal energy presentsarroyo instruments llc view allphotonics dictionary mediaquantum cascade lasera quantum cascade laser qcl is a type of semiconductor laser that emits light in the mid to farinfrared portion of the electromagnetic spectrum quantum cascade lasers offer many benefits theyreference chartslaser timelinelaser spectrum chartphotonics timeline view allcoursesmedical laser safety officer training2industrial laser safety officer trainingmedical laser safety officer trainingeducational institutionssocieties  associationsuniversities  research centers media view allfeaturededmund optics  polarization overview  part  polarization basicsedmund optics incnew scale technologies  developers kits for beam steering and mirror positioningnew scale technologies inc view alllight mattersbeacons lighting the skies over new england  light matters photonics media view allmedia channelsfeatured videososa centenniallight matters newscasteditorial videoseducational videosbreaking through podcastsingular expressions podcast webinars view all webinars  pm edtmobile hyperspectral imagers implementations and applicationsthis webinar will provide an overview of the state of the art in hyperspectral imaging the major2 pm estpractical solutions for laser safetyno laser user wishes to hurt themselves or others or damage expensive equipment nevertheless5 am estnext generation d printing the emergence of enabling materialsthreedimensional printing technology has the potential to eventually dissolve the boundaries20 pm estpbm  photobiomodulation basicsalthough photobiomodulation pbm is gaining acceptance the field is still in its infancy and many participate view all webinars suggest a topic  become a presenter become a sponsor events view all featured events augmicroscopy  microanalysis   st louis mo united statesthe mm the microscopy society of america msa and the microanalysis society mas conference is a scientific meeting and gathering of microscopy and microanalysis professionals academicsaugspie optics  photonics   san diego ca united statesoptics  photonics is the meeting where the latest research in optical engineering and applications nanotechnology sustainable energy organic photonics and astronomical instrumentation is view all upcoming events julnusod copenhagen denmarkjulosa advanced photonics congress new orleans la united statesjulosa optical sensorsnew orleans la united states view all event coverage prism awards for photonics innovation subscribe to trade show sneak previews submit an event listing share complete the form below to email this page to a friend your name  your email  to email  subject photonicscom page suggestion page title page link httpswwwphotonicscomarticleaspxaid544 comments one of your friends has shared a page with youyou can click the link above to view this page lumithera wins k grant for pbm devices biophotonicsaug  seattle — lumithera inc has received a  matching grant from the washington state life sciences discovery fund lsdf to commercialize devices for noninvasive photobiomodulation pbm treatment of dry agerelated macular degeneration amd there are no approved treatments for dry amd except vitamin supplements said clark tedford lumitheras president and ceo the grant with investor matching funds will further support initiation of a pivotal clinical trial in subjects that have dry amd since the lsdf announcement we have secured the investor match and will prepare for a clinical trial later this year pbm also known as lowlevel light therapy lllt uses visible or nearir light to stimulate cellular function and healing lumithera said it is developing multiwavelength ledbased pbm devices for ophthalmological use the new lsdsf grant also provides for collaboration between lumithera and the product creation studio ltd pcs a seattle design house last year lumithera received a  lsdf seed grant which it used to build a prototype instrument with pcs the use of pbm could give a large number of patients a noninvasive treatment wherein there are no alternatives said dr robert devenyi ophthalmologistinchief and director of retinal services at the university of toronto if it can slow the progression of vision loss that would be a tremendous advance in the field devenyi along with lumithera founders dr robert dotson and graham merry reported in a  study that pbm treatments resulted in positive and significant changes to visual acuity and contrast sensitivity in nine patients with amd for more information visit wwwlumitheracom explore related content glossaryphotobiomodulationalso known as pbm an event in which nonionizing optical radiation in the visible and nearinfrared nir spectral range is absorbed by endogenous chromophores to elicit photophysical and photochemical events at various biological scales photobiomodulation therapy pbmt is a form of light therapy based on the concepts of pbm and uses light in the visible and nir spectra to cause physiological changes and clinical benefitsophthalmologythe branch of medicine involved in the study of the anatomy functions diseases and treatments of the eye more related latest related by topic hayne developing quantum technology patent for telecommunicationsbusinessuniversity of arizona receives surveillance grant for border patrolamericasbrandon born awarded  teddi c laurin scholarshiplight speednot childs playbiophotonics businessamericaswashingtonlumitherabiophotonicsphotobiomodulationpbmlow level light therapyllltophthalmologyage related macular degenerationamdrapidscanlight speed the ability to post comments on photonicscom is one benefit of a free photonicscom membership please login or register for free to post comments login register latest headlines better materials could advance design of dielectric nanophotonic devices  hours agolightactivated gene expression could uncover cancer therapies  day agouniversity of arizona receives surveillance grant for border patrol  day agohayne developing quantum technology patent for telecommunications  day agoan international meeting of optical minds  day ago view all latest products spectroradiometer sphereoptics gmbhultrafast framing camera specialised imagingoptimized bespoke ir lenses resolve optics ltdsurgical light merivaara corpsample illumination light source spectral evolution inclaser diode driver portable power systems inchypotenuse right angle prisms edmund optics inclighting cable nexans incwaveguide phase shifters pasternack enterprises incmodular ellipsometer horiba scientific view all photonics buyers guide search more than 4 manufacturers and suppliers of photonics products and services worldwide featured categories companiesccd cameras companiesinstrument windows2 companiessapphire windowsfeatured companiesfisba llcheraeus tenevo llcmercron inc bookstorewebinar technology business champions’ guide to successful commercializationspecial archived webinar event this webinar is for anyone interested in developing andbuy now  terms  conditions privacy policy about us contact us our publications photonics spectra biophotonics industrial photonics europhotonics photonics showcase photonics buyers guide photonics handbook photonics dictionary enewsletters sections news features products white papers media light matters newscast webinars events  courses calendar browse by subject lasers optics imaging biophotonics industrial sensors  detectors test  measurement light sources fiber optics spectroscopy microscopy materials  coatings services subscribe login register advertise submit a press release list in the buyers guide buy wall charts terms  conditions privacy policy about us contact us back to top  photonics media x subscribe to biophotonics magazine  free lumithera named most innovative and promising medtech  ehealth company at biovision   the business journals menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases lists  awards lists all lists build your own lists people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations more… jobs find or post a job store subscriptions reprints  more how to grow your business advance your career thought leadership trends tips and insights from our partners subscribers manage your account about  contact about the business journals advertise help  faqs call center directory apps  syndication newsletters acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  press releases lumithera named most innovative and promising medtech  ehealth company at biovision  apr   am edt seattle april   prnewswire  lumithera® inc a clinical stage medical device company focused on delivering noninvasive photobiomodulation pbm therapies for ocular disorders and disease today announced it has been awarded the prestigious most innovative and promising medtech  ehealth company during biovision  in lyon france biovision is a highlevel investor event connecting industrial partners financial investors and the best medical technology biotechnology and ehealth startup and midsize companieshttpwwwbiovisionorg the most promising companies in each category are awarded based upon key criteria such as societal benefit market attractiveness innovative approach competitive position team structure and attractiveness for investment this is the second year that lumithera received the top award in its respective categories in  lumithera was the winner in the catalyzer category and this year it won first place in the investor category on a unanimous vote selected from a pool of applicants by a special biovision committee companies with the greatest potential to offer innovative health solutions were invited to present during the biovision forum in front of a jury comprised of leading european private and corporate investors in the life sciences  we are delighted that biovision has recognized the scientific clinical and product development progress lumithera made over the last year in advancing towards the commercial introduction of our innovative technology for treating dry age related macular degeneration amd one of the leading causes of blindness in the world said clark tedford phd chief executive officer we are honored to have received this second award as we prepare to bring this important therapy to the millions of patients suffering from dry amd who have no other treatment alternatives about age related macular degeneration amd agerelated macular degeneration amd accounts for  of all blindness worldwide and is the most common cause of blindness according to the world health organization disease prevalence is likely to increase due to population aging approximately 5 of amd is the dry form of the disease the emotional and socioeconomic impact of amd is large because vision impairment caused by the disease which primarily affects central straighton rather than peripheral side vision can severely impact daily activities such as reading and driving about lumithera inc lumithera inc is a developmentalstage medical device company initially focused on treating patients affected by dry agerelated macular degeneration the companys expertise is in the application of photobiomodulation pbm using noninvasive light emitting diodes led for acute and chronic ocular diseases and disorders the company is developing an ophthalmic led officebased instrument to be used in multiple ocular conditions or disorders as noninvasive medical treatments two clinical studies have demonstrated clinical and pathological benefits of pbm in treating subjects with dry amd the recent torpa ii clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological drusen following imaging analysis were published in december  in acta ophthalmologica a top peerreviewed ophthalmology journal the company is currently testing their lt device in a thirty subject dry amd study partially supported by the national eye institute this randomized sham controlled clinical study is fully enrolled and interim outcomes are expected in  the lt is currently in clinical trials and is not ce marked nor fda k cleared  lumithera inc all rights reserved visit the companys website at wwwlumitheracom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleaseslumitheranamedmostinnovativeandpromisingmedtechehealthcompanyatbiovision44html source lumithera inc the information on this page is provided by pr newswire all rights reserved reproduction or redistribution of this content without prior written consent from pr newswire is strictly prohibited is not responsible for this content learn more about this service about pr newswire the information on this page is provided by pr newswire the business journals is not responsible for this content learn more   page not found  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street page not found sorry the page youre looking for is not available you might want to try our homepage our most popular stories  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers